IRIS
RUSSO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.787
NA - Nord America 1.365
AS - Asia 792
SA - Sud America 301
AF - Africa 17
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.263
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.332
RU - Federazione Russa 891
SG - Singapore 312
PL - Polonia 281
BR - Brasile 264
CN - Cina 223
IE - Irlanda 177
SE - Svezia 135
IT - Italia 117
HK - Hong Kong 85
FR - Francia 80
VN - Vietnam 50
IN - India 27
DE - Germania 24
FI - Finlandia 19
CA - Canada 17
BE - Belgio 16
ID - Indonesia 16
AR - Argentina 14
UA - Ucraina 12
BD - Bangladesh 11
GB - Regno Unito 11
TR - Turchia 8
MX - Messico 7
PH - Filippine 7
UZ - Uzbekistan 7
CO - Colombia 6
IQ - Iraq 6
JP - Giappone 6
ZA - Sudafrica 6
EC - Ecuador 5
PK - Pakistan 5
AT - Austria 4
ES - Italia 4
KR - Corea 4
MY - Malesia 4
NL - Olanda 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
NP - Nepal 3
OM - Oman 3
AO - Angola 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
EG - Egitto 2
HN - Honduras 2
IL - Israele 2
JM - Giamaica 2
KE - Kenya 2
KG - Kirghizistan 2
LT - Lituania 2
PE - Perù 2
PY - Paraguay 2
SA - Arabia Saudita 2
UY - Uruguay 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
CL - Cile 1
CR - Costa Rica 1
DZ - Algeria 1
EU - Europa 1
GT - Guatemala 1
GY - Guiana 1
IR - Iran 1
JO - Giordania 1
MD - Moldavia 1
MN - Mongolia 1
MZ - Mozambico 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
Totale 4.263
Salva come PNG Salva come JPEG
Città #
Warsaw 278
Ashburn 262
Moscow 245
Dublin 177
Chandler 168
Singapore 159
Dallas 90
Hong Kong 85
Beijing 74
Nyköping 68
New York 48
Messina 45
Ann Arbor 43
The Dalles 43
San Jose 40
Princeton 35
Dearborn 34
Jacksonville 34
Lauterbourg 27
Los Angeles 27
Medford 27
Des Moines 24
Council Bluffs 19
Dong Ket 18
Cambridge 17
Brussels 16
Fort Washington 14
São Paulo 14
Wilmington 14
Buffalo 13
Ho Chi Minh City 13
Houston 11
Jakarta 11
Jinan 11
Tianjin 11
Munich 10
Belo Horizonte 8
Chennai 8
Guangzhou 8
Redondo Beach 8
Shenyang 8
Toronto 8
Woodbridge 8
Boardman 7
Falls Church 7
Hanoi 7
San Mateo 7
Seattle 7
Stockholm 7
Tashkent 7
Brooklyn 6
Hillsboro 6
Pune 6
San Francisco 6
Hebei 5
Nanjing 5
Orem 5
Rio de Janeiro 5
Santa Clara 5
Tokyo 5
Anagni 4
Brasília 4
Cagliari 4
Chicago 4
Curitiba 4
Dhaka 4
Dongdaemun-gu 4
Fairfield 4
Juiz de Fora 4
London 4
Mexico City 4
Mumbai 4
Nanchang 4
Nuremberg 4
Redwood City 4
Shanghai 4
Shenzhen 4
Zhengzhou 4
Amsterdam 3
Aracaju 3
Atlanta 3
Barretos 3
Bogotá 3
Brockport 3
Caloocan 3
Campinas 3
Diadema 3
Frankfurt am Main 3
Hangzhou 3
Indaiatuba 3
Johannesburg 3
Joinville 3
Manaus 3
Milan 3
Mogi Mirim 3
Montreal 3
Radomsko 3
Turku 3
Abidjan 2
Americana 2
Totale 2.520
Salva come PNG Salva come JPEG
Nome #
Exosomal PD-L1 expression and dynamic changes of immune response associated cytokines as predictive biomarkers for immune checkpoint blockage with PD-1/PD-L1 inhibitors in advanced/metastatic non-small cell lung cancer 263
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 242
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 204
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 185
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 184
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 179
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 173
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 171
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 164
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 154
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 154
Liquid biopsy tracking of lung tumor evolutions over time 149
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 147
Impact of erlotinib on overall survival in non small cell lung cancer patients: is the post progression survival a new paradigm? 146
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 145
How I treat ALK-positive non-small cell lung cancer 141
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site 140
Impact of circulating microRNAs mir-22, mir-24 and mir-34a on response to pemetrexed in patients with non small cell lung cancer 135
1995PApplication of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC patients (pts): Is it feasible and reliable? 134
Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario 133
NSCLC and HER2: between lights and shadows 131
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 129
Immunotherapy use in patients with HIV and non-small-cell lung cancer: Current data 128
Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study 125
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation 121
Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC 117
Acquired resistance in oncogene-addicted non-small-cell lung cancer 113
Treatment option for small cell lung cancer: does lanreotide represent a new choice? 74
Re-treatment with gefitinib or treatment with erlotinib after gefitinib failure in responsive non small cell lung cancers: new strategies to overcome acquired resistance. 72
Totale 4.353
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.229
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.229
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202120 0 0 0 0 0 0 0 0 0 0 0 20
2021/2022231 1 24 7 7 9 9 14 9 1 41 36 73
2022/2023533 38 56 19 44 35 48 7 45 221 3 12 5
2023/2024149 8 25 8 9 12 60 2 10 1 1 0 13
2024/2025637 3 5 7 36 60 18 52 155 125 28 45 103
2025/20261.974 102 110 127 112 160 393 255 283 285 84 24 39
Totale 4.353